| Not Yet Recruiting | Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health E NCT07280871 | Luxembourg Institute of Health | — |
| Recruiting | Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis NCT07477639 | Tr1X, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participant NCT07483450 | Hoffmann-La Roche | Phase 4 |
| Not Yet Recruiting | A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis NCT06900192 | Stanford University | Phase 1 |
| Recruiting | Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis NCT07426991 | Heinrich-Heine University, Duesseldorf | — |
| Active Not Recruiting | Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration NCT05893225 | University Hospital, Antwerp | Phase 2 |
| Completed | Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical) NCT05974839 | State University of New York at Buffalo | — |
| Completed | Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS NCT05974852 | State University of New York at Buffalo | — |
| Unknown | The Influence of HIIT Versus MCT on Cardiorespiratory Fitness in PPMS NCT05229861 | Klinik Valens | N/A |
| Completed | A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pha NCT05232825 | Hoffmann-La Roche | Phase 3 |
| Completed | Metformin Treatment in Progressive Multiple Sclerosis NCT05349474 | University of California, Los Angeles | EARLY_Phase 1 |
| Unknown | Gray Matter Demyelination in Primary Progressive MS at 7T NCT04977622 | Danish Research Centre for Magnetic Resonance | — |
| Withdrawn | Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS NCT05029609 | Tiziana Life Sciences LTD | Phase 1 |
| Active Not Recruiting | Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis NCT04688788 | Rigshospitalet, Denmark | Phase 3 |
| Completed | Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis NCT04943289 | Joanne Kurtzberg, MD | Phase 1 |
| Completed | Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib ( NCT04458051 | Sanofi | Phase 3 |
| Recruiting | SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis NCT03783416 | Queen Mary University of London | Phase 1 |
| Unknown | Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714 NCT03691077 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus NCT03562975 | University of South Florida | — |
| Completed | Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis NCT03493841 | Rebecca Spain | Phase 1 |
| Active Not Recruiting | Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS NCT03362294 | Mapi Pharma Ltd. | Phase 2 |
| Terminated | Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis NCT03283826 | Atara Biotherapeutics | Phase 1 / Phase 2 |
| Completed | Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis NCT02959658 | Rigshospitalet, Denmark | Phase 2 |
| Completed | Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis NCT03094364 | University of Massachusetts, Lowell | N/A |
| Completed | Mitochondrial Dysfunction and Disease Progression NCT02549703 | Icahn School of Medicine at Mount Sinai | — |
| Completed | A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safet NCT02284568 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 |
| Completed | A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients NCT02253264 | Johns Hopkins University | Phase 1 |
| Unknown | Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS NCT02273635 | Innobioscience SpA | Phase 1 / Phase 2 |
| Terminated | ACTH in Progressive Forms of MS NCT01950234 | University of Minnesota | Phase 2 |
| Completed | A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS NCT02208050 | University College Dublin | Phase 4 |
| Completed | Idebenone for Primary Progressive Multiple Sclerosis NCT01854359 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Completed | Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study NCT01776060 | Duke University | — |
| Unknown | Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition NCT01466114 | University of California, Los Angeles | Phase 2 |
| Completed | Tear Analysis in the Diagnosis of Multiple Sclerosis NCT02016222 | Lille Catholic University | N/A |
| Completed | Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis NCT01191996 | Innate Immunotherapeutics | Phase 1 / Phase 2 |
| Completed | Natalizumab Treatment of Progressive Multiple Sclerosis NCT01077466 | Rigshospitalet, Denmark | Phase 2 |
| Completed | Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS) NCT00950248 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Terminated | This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, NCT00731692 | Novartis Pharmaceuticals | Phase 3 |